Sugi Predict

Sugi Predict / Compounds / SCHEMBL377852

SCHEMBL377852

SCHEMBL377852

COc1cc(OC)c2c(=O)[nH]c(-c3ccc(N4C[C@@H](C)N[C@@H](C)C4)cc3)nc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 8/20 0.54
▸ HDAC3 O15379 9/20 0.52
▸ HDAC4 P56524 9/20 0.52
▸ HDAC1 Q13547 9/20 0.52
▸ HDAC7 Q8WUI4 9/20 0.52
▸ HDAC2 Q92769 9/20 0.52
▸ HDAC10 Q969S8 9/20 0.52
▸ HDAC11 Q96DB2 9/20 0.52
▸ HDAC8 Q9BY41 9/20 0.52
▸ HDAC6 Q9UBN7 9/20 0.52
▸ HDAC9 Q9UKV0 9/20 0.52
▸ HDAC5 Q9UQL6 9/20 0.52
▸ BRD2 P25440 2/20 0.49
▸ BRD1 O95696 1/20 0.49
▸ PARP1 P09874 1/20 0.49
▸ IL17A Q16552 1/20 0.49
▸ CSNK1A1 P48729 1/20 0.47
▸ CSNK1D P48730 1/20 0.47
▸ CSNK1E P49674 1/20 0.47
▸ CSNK1G2 P78368 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377776 0.89 BRD4 (0.52) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL10279776 0.89 BRD4 (0.52) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL31115575 0.87 BRD4 (0.51) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL377806 0.87 BRD4 (0.51) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL378203 0.86 BRD4 (0.54) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL617075 0.86 BRD4 (0.54) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL348652 0.84 BRD4 (0.58) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL30053496 0.84 BRD4 (0.58) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL30053201 0.84 KDM4E (0.65) BRD4HDAC3HDAC4HDAC1HDAC7
SCHEMBL378020 0.84 BRD4 (0.58) BRD4HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP claimed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 — — US claimed
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2016-05-19 — — US claimed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US claimed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP claimed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO claimed
EP-2408454-B1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP (CA) 2024-07-24 — — EP disclosed
US-11407719-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2022-08-09 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2021-03-11 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-10882828-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2021-01-05 — — US disclosed
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2019-04-25 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS HEPALINK (HONG KONG) LIMITED (HK) 2012-02-16 — — US disclosed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP disclosed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407719-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885HDAC3 1263/4885HDAC4 981/4885
US-20160137613-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885HDAC3 1275/4885HDAC4 910/4885
US-20130281399-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION PHKB, BAZ2A, EP300 BRD4 10/4885HDAC3 54/4885HDAC4 84/4885
US-10882828-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885HDAC3 1263/4885HDAC4 981/4885
US-20210070716-A1 ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 744/4885HDAC3 1263/4885HDAC4 981/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 BRD4 744/4885HDAC3 1263/4885HDAC4 981/4885
US-20190119222-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885HDAC3 1275/4885HDAC4 910/4885
US-20120040954-A1 NOVEL ANTI-INFLAMMATORY AGENTS VCAM1, ICAM1, IL6 BRD4 700/4885HDAC3 1275/4885HDAC4 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.